Compare Novo Nordisk A/S (NVO) vs Omnicom Group Inc. (OMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Omnicom Group Inc. — how do they compare? Novo Nordisk A/S trades at $49.32 (market cap $220.53B), while Omnicom Group Inc. trades at $79.22 (market cap $23.48B). The key difference: Novo Nordisk A/S is far larger — about 9.4× Omnicom Group Inc.'s market cap, and Omnicom Group Inc. pays the higher dividend (3.88%). Which is the better fit depends on your goals.
| NVO | OMC | |
|---|---|---|
Market Cap | $220.53B | $23.48B |
Sector | Health | Media |
52-Week High | $71.70 | $85.80 |
52-Week Low | $35.29 | $67.27 |
Enterprise Value | $239.49B | $30.70B |
Dividend Yield | 3.63% | 3.88% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →
